EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans

Gissette Reyes-Soffer iD, Anastasiya Matveyenko, James Lignos, Nelsa Matienzo iD, Leinys S Santos Baez iD, Antonio Hernandez-Ono iD, Lau Yung, Renu Nandakumar, Sasha A Singh iD, Masanori Aikawa iD, Richard George iD, Henry N Ginsberg iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2024

DOI: 10.1161/atvbaha.123.320387 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. Verfasst von Gissette Reyes-Soffer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (G.R.-S., A.M., J.L., N.M., L.S.S.B., A.H.-O., L.Y.,…. Hauptthemen laut MEDLINE: Phosphatidylcholine-Sterol O-Acyltransferase, Recombinant Proteins, Cross-Over Studies, Apolipoprotein A-I. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: LCAT (lecithin cholesterol acyl transferase) catalyzes the conversion of unesterified, or free cholesterol, to cholesteryl ester, which moves from the surface of HDL (high-density lipoprotein) into the neutral lipid core. As this iterative process continues, nascent lipid-poor HDL is converted to a series of larger, spherical cholesteryl ester–enriched HDL particles that can be cleared by the liver in a process that has been termed reverse cholesterol transport. METHODS: We conducted a randomized, placebocontrolled, crossover study in 5 volunteers with atherosclerotic cardiovascular disease, to examine the effects of an acute increase of recombinant human (rh) LCAT via intravenous administration (300-mg loading dose followed by 150 mg at 48 hours) on the in vivo metabolism of HDL APO (apolipoprotein)A1 and APOA2, and the APOB100-lipoproteins, very low density, intermediate density, and low-density lipoproteins. RESULTS: As expected, recombinant human LCAT treatment significantly increased HDL-cholesterol (34.9 mg/dL; P ≤0.001), and this was mostly due to the increase in cholesteryl ester content (33.0 mg/dL; P =0.014). This change did not affect the fractional clearance or production rates of HDL-APOA1 and HDL-APOA2. There were also no significant changes in the metabolism of APOB100-lipoproteins. CONCLUSIONS: Our results suggest that an acute increase in LCAT activity drives greater flux of cholesteryl ester through the reverse cholesterol transport pathway without significantly altering the clearance and production of the main HDL proteins and without affecting the metabolism of APOB100-lipoproteins. Long-term elevations of LCAT might, therefore, have beneficial effects on total body cholesterol balance and atherogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphatidylcholine-Sterol O-AcyltransferaseRecombinant ProteinsCross-Over StudiesApolipoprotein A-ICholesterol, HDLApolipoprotein A-IIHumansMaleMiddle AgedFemaleCholesterol EstersAtherosclerosisApolipoprotein B-100AgedAdultLipoproteins

Stichwörter der Autor:innen

atherosclerosiscardiovascular diseaseslecithinlipoproteinliver

Substanzen

Phosphatidylcholine-Sterol O-AcyltransferaseRecombinant ProteinsApolipoprotein A-ILCAT protein, humanCholesterol, HDLAPOA1 protein, humanApolipoprotein A-IICholesterol EstersAPOA2 protein, humanApolipoprotein B-100

Autor:innen und Institutionen

  • Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York (G.R.-S., A.M., J.L., N.M., L.S.S.B., A.H.-O., L.Y., H.N.G.).
  • Irving Institute for Clinical and Translations Research (R.N.) and Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York.
  • Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Department of Medicine (S.A.S., M.A.), Brigham Women's Hospital, Harvard Medical School, Boston, MA.
  • Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine (M.A.), Brigham Women's Hospital, Harvard Medical School, Boston, MA.
  • Channing Division of Network Medicine, Department of Medicine (M.A.), Brigham Women's Hospital, Harvard Medical School, Boston, MA.
  • Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD (R.G.).

ORCID-Profile: Gissette Reyes-Soffer, Nelsa Matienzo, Leinys S Santos Baez, Antonio Hernandez-Ono, Sasha A Singh, Masanori Aikawa, Richard George, Henry N Ginsberg

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Reyes-Soffer, G., Matveyenko, A., Lignos, J., Matienzo, N., Santos Baez, L. S., Hernandez-Ono, A., Yung, L., Nandakumar, R., Singh, S. A., Aikawa, M., George, R., & Ginsberg, H. N. (2024). Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.320387

Vancouver

Reyes-Soffer G, Matveyenko A, Lignos J, Matienzo N, Santos Baez LS, Hernandez-Ono A, et al. Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. doi:10.1161/atvbaha.123.320387

BibTeX
@article{ReyesSoffer2024,
  author = {Reyes-Soffer, Gissette and Matveyenko, Anastasiya and Lignos, James and Matienzo, Nelsa and Santos Baez, Leinys S and Hernandez-Ono, Antonio and Yung, Lau and Nandakumar, Renu and Singh, Sasha A and Aikawa, Masanori and George, Richard and Ginsberg, Henry N},
  title = {Effects of Recombinant Human Lecithin Cholesterol Acyltransferase on Lipoprotein Metabolism in Humans},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2024},
  doi = {10.1161/atvbaha.123.320387}
}
Kostenlos starten →